Novo Nordisk Aktie
60,91
EUR
+1,96
EUR
+3,32
%
60,61
EUR
+2,28
EUR
+3,91
%
Werbung
Novo Nordisk Aktie Analyse
04.03.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
04.03.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
04.03.22 | Novo Nordisk Hold | Deutsche Bank AG | |
28.02.22 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
15.02.22 | Novo Nordisk Overweight | Barclays Capital | |
08.02.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
07.02.22 | Novo Nordisk Hold | Deutsche Bank AG | |
03.02.22 | Novo Nordisk Neutral | UBS AG | |
Werbung
|
|||
03.02.22 | Novo Nordisk Outperform | Bernstein Research | |
03.02.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
03.02.22 | Novo Nordisk Hold | Deutsche Bank AG | |
03.02.22 | Novo Nordisk Neutral | Credit Suisse Group | |
02.02.22 | Novo Nordisk Outperform | Bernstein Research | |
02.02.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
02.02.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
02.02.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
31.01.22 | Novo Nordisk Overweight | Barclays Capital | |
26.01.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
26.01.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
25.01.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
24.01.22 | Novo Nordisk Outperform | Bernstein Research | |
06.01.22 | Novo Nordisk Hold | Deutsche Bank AG | |
06.01.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
04.01.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
04.01.22 | Novo Nordisk Outperform | Bernstein Research | |
21.12.21 | Novo Nordisk Hold | Kepler Cheuvreux | |
21.12.21 | Novo Nordisk Overweight | Barclays Capital | |
20.12.21 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
07.12.21 | Novo Nordisk Buy | Deutsche Bank AG | |
07.12.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
29.11.21 | Novo Nordisk Buy | Deutsche Bank AG | |
26.11.21 | Novo Nordisk Neutral | UBS AG | |
26.11.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
26.11.21 | Novo Nordisk Outperform | Bernstein Research | |
22.11.21 | Novo Nordisk Overweight | Barclays Capital | |
19.11.21 | Novo Nordisk Neutral | UBS AG | |
18.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
11.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
04.11.21 | Novo Nordisk Neutral | Credit Suisse Group | |
04.11.21 | Novo Nordisk Overweight | Barclays Capital | |
04.11.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
03.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
03.11.21 | Novo Nordisk Outperform | Bernstein Research | |
03.11.21 | Novo Nordisk Neutral | UBS AG | |
03.11.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
01.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
29.10.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
29.10.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
27.10.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
18.10.21 | Novo Nordisk Overweight | Barclays Capital |
Werbung
Werbung